Chengdu Huasun Group Inc Ltd

SHE:000790 China Drug Manufacturers - Specialty & Generic
Market Cap
$353.63 Million
CN¥2.59 Billion CNY
Market Cap Rank
#13095 Global
#3322 in China
Share Price
CN¥4.16
Change (1 day)
-1.42%
52-Week Range
CN¥3.39 - CN¥4.55
All Time High
CN¥21.66
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Chengdu huasun technology group Inc. , LTD. manufactures and sells medicines, bio-pharmaceutical products, and building steel structures. The company manufactures modern Chinese medicines, Chinese patent medicines, chemical medicines, and drugs. It also engages in the research and development, production, and sale of biological products and biotechnology drugs; and medicines for the treatment of … Read more

Chengdu Huasun Group Inc Ltd (000790) - Net Assets

Latest net assets as of September 2025: CN¥949.82 Million CNY

Based on the latest financial reports, Chengdu Huasun Group Inc Ltd (000790) has net assets worth CN¥949.82 Million CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.86 Billion) and total liabilities (CN¥911.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥949.82 Million
% of Total Assets 51.02%
Annual Growth Rate 7.46%
5-Year Change 17.04%
10-Year Change 83.08%
Growth Volatility 12.16

Chengdu Huasun Group Inc Ltd - Net Assets Trend (1995–2024)

This chart illustrates how Chengdu Huasun Group Inc Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Chengdu Huasun Group Inc Ltd (1995–2024)

The table below shows the annual net assets of Chengdu Huasun Group Inc Ltd from 1995 to 2024.

Year Net Assets Change
2024-12-31 CN¥1.07 Billion -0.78%
2023-12-31 CN¥1.08 Billion +7.05%
2022-12-31 CN¥1.01 Billion +2.45%
2021-12-31 CN¥981.44 Million +7.56%
2020-12-31 CN¥912.45 Million +3.60%
2019-12-31 CN¥880.71 Million +5.40%
2018-12-31 CN¥835.55 Million -0.39%
2017-12-31 CN¥838.86 Million +25.98%
2016-12-31 CN¥665.85 Million +14.14%
2015-12-31 CN¥583.35 Million -7.74%
2014-12-31 CN¥632.30 Million +8.00%
2013-12-31 CN¥585.45 Million +7.25%
2012-12-31 CN¥545.88 Million +10.83%
2011-12-31 CN¥492.53 Million +6.88%
2010-12-31 CN¥460.83 Million +14.51%
2009-12-31 CN¥402.43 Million -2.89%
2008-12-31 CN¥414.42 Million -0.03%
2007-12-31 CN¥414.55 Million -3.09%
2006-12-31 CN¥427.78 Million +1.03%
2005-12-31 CN¥423.41 Million -2.57%
2004-12-31 CN¥434.58 Million +4.18%
2003-12-31 CN¥417.14 Million +2.33%
2002-12-31 CN¥407.64 Million -3.54%
2001-12-31 CN¥422.61 Million +55.78%
2000-12-31 CN¥271.28 Million +14.68%
1999-12-31 CN¥236.56 Million +7.29%
1998-12-31 CN¥220.50 Million +10.30%
1997-12-31 CN¥199.91 Million +22.83%
1996-12-31 CN¥162.75 Million +22.77%
1995-12-31 CN¥132.57 Million --

Equity Component Analysis

This analysis shows how different components contribute to Chengdu Huasun Group Inc Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 3360.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥215.90 Million 21.04%
Common Stock CN¥623.72 Million 60.80%
Other Comprehensive Income CN¥143.55 Million 13.99%
Other Components CN¥42.73 Million 4.16%
Total Equity CN¥1.03 Billion 100.00%

Chengdu Huasun Group Inc Ltd Competitors by Market Cap

The table below lists competitors of Chengdu Huasun Group Inc Ltd ranked by their market capitalization.

Company Market Cap
Nathans Famous Inc
NASDAQ:NATH
 		$286.17 Million
FutureChem Co.Ltd
KQ:220100
 		$286.19 Million
Oriental Union Chemical Corp
TW:1710
 		$286.20 Million
ZJBC Information Technology Co Ltd
SHE:000889
 		$286.23 Million
Pubmatic Inc
NASDAQ:PUBM
 		$286.11 Million
Banco Products (I) Limited
NSE:BANCOINDIA
 		$286.08 Million
Maravai Lifesciences Holdings Inc
NASDAQ:MRVI
 		$285.91 Million
Lenzing AG
LSE:0NCV
 		$285.86 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Chengdu Huasun Group Inc Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,033,194,655 to 1,025,895,578, a change of -7,299,077 (-0.7%).
  • Net loss of 6,690,166 reduced equity.
  • Dividend payments of 20,702,219 reduced retained earnings.
  • Share repurchases of 10,137,649 reduced equity.
  • Other comprehensive income increased equity by 289,596,166.
  • Other factors decreased equity by 259,365,209.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-6.69 Million -0.65%
Dividends Paid CN¥20.70 Million -2.02%
Share Repurchases CN¥10.14 Million -0.99%
Other Comprehensive Income CN¥289.60 Million +28.23%
Other Changes CN¥-259.37 Million -25.28%
Total Change CN¥- -0.71%

Book Value vs Market Value Analysis

This analysis compares Chengdu Huasun Group Inc Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.71x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 18.65x to 2.71x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.22 CN¥4.16 x
1996-12-31 CN¥0.27 CN¥4.16 x
1997-12-31 CN¥0.34 CN¥4.16 x
1998-12-31 CN¥0.35 CN¥4.16 x
1999-12-31 CN¥0.37 CN¥4.16 x
2000-12-31 CN¥0.41 CN¥4.16 x
2001-12-31 CN¥0.66 CN¥4.16 x
2002-12-31 CN¥0.66 CN¥4.16 x
2003-12-31 CN¥0.68 CN¥4.16 x
2004-12-31 CN¥0.68 CN¥4.16 x
2005-12-31 CN¥0.66 CN¥4.16 x
2006-12-31 CN¥0.67 CN¥4.16 x
2007-12-31 CN¥0.65 CN¥4.16 x
2008-12-31 CN¥0.66 CN¥4.16 x
2009-12-31 CN¥0.68 CN¥4.16 x
2010-12-31 CN¥0.75 CN¥4.16 x
2011-12-31 CN¥0.80 CN¥4.16 x
2012-12-31 CN¥0.89 CN¥4.16 x
2013-12-31 CN¥0.95 CN¥4.16 x
2014-12-31 CN¥1.03 CN¥4.16 x
2015-12-31 CN¥0.95 CN¥4.16 x
2016-12-31 CN¥1.08 CN¥4.16 x
2017-12-31 CN¥1.36 CN¥4.16 x
2018-12-31 CN¥1.36 CN¥4.16 x
2019-12-31 CN¥1.43 CN¥4.16 x
2020-12-31 CN¥1.48 CN¥4.16 x
2021-12-31 CN¥1.58 CN¥4.16 x
2022-12-31 CN¥1.62 CN¥4.16 x
2023-12-31 CN¥1.49 CN¥4.16 x
2024-12-31 CN¥1.53 CN¥4.16 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Chengdu Huasun Group Inc Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -0.65%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -0.77%
  • • Asset Turnover: 0.38x
  • • Equity Multiplier: 2.19x
  • Recent ROE (-0.65%) is below the historical average (6.29%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 11.67% 24.32% 0.40x 1.19x CN¥2.21 Million
1996 18.54% 27.37% 0.60x 1.13x CN¥13.91 Million
1997 18.59% 23.72% 0.66x 1.20x CN¥17.17 Million
1998 16.11% 21.46% 0.50x 1.49x CN¥12.84 Million
1999 9.95% 15.31% 0.39x 1.68x CN¥-111.94K
2000 10.02% 13.74% 0.41x 1.79x CN¥59.45K
2001 5.69% 10.02% 0.39x 1.45x CN¥-16.91 Million
2002 4.73% 9.87% 0.33x 1.46x CN¥-20.64 Million
2003 2.44% 5.86% 0.28x 1.49x CN¥-30.37 Million
2004 0.34% 0.70% 0.28x 1.69x CN¥-38.95 Million
2005 0.56% 1.18% 0.26x 1.81x CN¥-37.04 Million
2006 1.35% 2.41% 0.32x 1.75x CN¥-34.58 Million
2007 0.47% 0.67% 0.39x 1.81x CN¥-37.03 Million
2008 1.30% 1.41% 0.46x 1.99x CN¥-34.27 Million
2009 1.80% 1.89% 0.54x 1.77x CN¥-32.90 Million
2010 2.71% 2.55% 0.64x 1.67x CN¥-33.51 Million
2011 4.23% 3.78% 0.64x 1.75x CN¥-28.39 Million
2012 6.17% 5.80% 0.64x 1.67x CN¥-20.92 Million
2013 8.55% 7.61% 0.65x 1.73x CN¥-8.48 Million
2014 10.45% 12.51% 0.50x 1.68x CN¥2.86 Million
2015 -6.41% -8.07% 0.50x 1.59x CN¥-95.74 Million
2016 12.39% 14.34% 0.53x 1.64x CN¥15.91 Million
2017 20.46% 29.05% 0.45x 1.58x CN¥87.78 Million
2018 3.73% 4.92% 0.58x 1.30x CN¥-52.39 Million
2019 7.00% 8.27% 0.65x 1.29x CN¥-26.44 Million
2020 4.11% 4.94% 0.67x 1.25x CN¥-53.70 Million
2021 5.70% 5.83% 0.71x 1.38x CN¥-42.01 Million
2022 4.11% 4.72% 0.52x 1.67x CN¥-59.09 Million
2023 2.68% 2.76% 0.47x 2.06x CN¥-75.66 Million
2024 -0.65% -0.77% 0.38x 2.19x CN¥-109.28 Million

Industry Comparison

This section compares Chengdu Huasun Group Inc Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Chengdu Huasun Group Inc Ltd (000790) CN¥949.82 Million 11.67% 0.96x $286.16 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million